Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29282054 | 0.84 | POLB (0.35) | FFAR2ACEALDH1A1 | |
| SCHEMBL22444297 | 0.83 | FFAR2 (0.35) | FFAR2ACEALDH1A1 | |
| SCHEMBL22371723 | 0.83 | FFAR2 (0.35) | FFAR2ACEALDH1A1 | |
| SCHEMBL20819885 | 0.83 | FFAR2 (0.35) | FFAR2ACEALDH1A1 | |
| SCHEMBL28408623 | 0.83 | FFAR2 (0.35) | FFAR2ACEALDH1A1 | |
| SCHEMBL20819892 | 0.83 | FFAR2 (0.35) | FFAR2ACEALDH1A1 | |
| SCHEMBL30918117 | 0.80 | FFAR2 (0.32) | FFAR2ACE | |
| SCHEMBL29282048 | 0.80 | FFAR2 (0.32) | FFAR2ACE | |
| SCHEMBL29282049 | 0.80 | FFAR2 (0.32) | FFAR2ACE | |
| SCHEMBL3826730 | 0.78 | ACE (0.37) | FFAR2ACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4208452-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| US-7094800-B2 | pyrrolizinones, e.g., (3S,6R,7aS)-6-amino-5-oxo-hexahydro-pyrrolizine-3-carbonitrile trifluoroacetate, used for reducing blood sugar, treating type 2 diabetes, and treating insulin resistance | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-22 | — | — | US | disclosed |
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | CYP11B2, SLC5A2, CYP11B1 | FFAR2 891/4885ACE 206/4885ALDH1A1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.